Integrated analysis of 34 microarray datasets reveals CBX3 as a diagnostic and prognostic biomarker in glioblastoma

Abstract

Background Glioblastomas have a high degree of malignancy, high recurrence rate, high mortality rate, and low cure rate. Searching for new markers of glioblastomas is of great significance for improving the diagnosis, prognosis and treatment of glioma. Methods Using the GEO public database, we combined 34 glioma microarray datasets containing 1893 glioma samples and conducted genetic data mining through statistical analysis, bioclustering, and pathway analysis. The results were validated in TCGA, CGGA, and internal cohorts. We further selected a gene for subsequent experiments and conducted cell proliferation and cell cycle analyses to verify the biological function of this gene. Results Eight glioblastoma-specific differentially expressed genes were screened using GEO. In the TCGA and CGGA cohorts, patients with high CBX3 , BARD1 , EGFR , or IFRD1 expression had significantly shorter survival but patients with high GUCY1A3 or MOBP expression had significantly longer survival than patients with lower expression of these genes. After reviewing the literature, we selected the CBX3 gene for further experiments. We confirmed that CBX3 was overexpressed in glioblastoma by immunohistochemical analysis of tissue microarrays and qPCR analysis of surgical specimens. The functional assay results showed that silencing CBX3 arrests the cell cycle in the G2/M phase, thereby weakening the cell proliferation ability. Conclusions We used a multidisciplinary approach to analyze glioblastoma samples in 34 microarray datasets, revealing novel diagnostic and prognostic biomarkers in patients with glioblastoma and providing a new direction for screening tumor markers. Electronic supplementary material The online version of this article (10.1186/s12967-019-1930-3) contains supplementary material, which is available to authorized users.

<p>CBX3 Promotes Gastric Cancer Progression and Affects Factors Related to Immunotherapeutic Responses</p>

“…32 Knocking down CBX3 can arrest cell cycle in the G2/M cell cycle transition, thereby suppressing the proliferation of cancer cells in pancreatic adenocarcinoma 33 and glioblastoma. 34 Similarly, our results show that CBX3 inhibition affects cell cycle transformation not only in G1/S phase but also in G2/M phase.…”

Heterogeneous EGFR, CDK4, MDM4, and PDGFRA Gene Expression Profiles in Primary GBM: No Association with Patient Survival

“…In recent years, accumulated evidence suggested that amplification of the EGFR and other genes might play a critical role in the oncogenesis and clinical behavior of GBM [22,26,27]. Despite this, with the exception of a recent study [28], no clear association has been reported in the literature between the GEP and the genetic alterations of individual genes in GBM [29]. In order to investigate the potential association between overexpression of EGFR, CDK4, MDM4, and PDGFRA, subsequent analysis of gene amplification was performed at the DNA level.…”

High expression levels of pyrimidine metabolic rate–limiting enzymes are adverse prognostic factors in lung adenocarcinoma: a study based on The Cancer Genome Atlas and Gene Expression Omnibus datasets

“…Because of the complexity of lung cancer [43], results derived from GEO and TCGA datasets were not always consistent with each other. Also, the difference in treatment protocol and microarray platform in individual study limited the further applications of these findings [44]. For example, CAD, CTPS, and DHODH had no prognostic effect in LUAD dataset but associated with the clinical outcomes in lung cancer patients derived from GEO datasets.…”